Glucocorticoids still are the most effective, broadly applicable, and cheapest immunosuppressive drugs used in the treatment of rheumatic conditions. In rheumatoid arthritis (RA) they are applied for their symptomatic effects but also for disease-modifying properties. The risk of adverse effects of glucocorticoid therapy in RA is dependent on patient (age, comorbidity, and comedication), glucocorticoid dose, type and route of administration, and treatment duration. Toxicity is important in treatment decisions, but for low-dose glucocorticoids, overestimation of the risk of adverse effects should be avoided. Monitoring safety of this therapy only requires that good follow-up of rheumatic patients in daily practice is extended with screening for osteoporosis, and pretreatment assessments of fasting blood glucose levels, risk factors for glaucoma, and a check for ankle oedema.